Johnson & Johnson Is Heading Toward A Major Patent Cliff
FROM THE WIRE · FINANCE.YAHOO.COM
Johnson & Johnson (NYSE: JNJ) faces upcoming patent expirations on key cancer drugs Imbruvica and Darzalex over the next several years. These expiries are part of a broader pharmaceutical industry patent cliff affecting multiple large drugmakers through the early 2030s.…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishJNJ faces upcoming patent expirations on key cancer drugs Imbruvica and Darzalex over the next several years.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Johnson & Johnson faces patent expirations on key cancer drugs Imbruvica and Darzalex over the next several years.
- 02Expirations are part of broader pharmaceutical industry patent cliff affecting multiple large drugmakers through early 2030s.
- 03Management is investing in research pipelines and dealmaking to prepare for revenue pressure.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets